Emergency siren button ‘accidentally pressed': Macon Co. EMA
MACON COUNTY, Ill. (WCIA) — An outdoor warning siren sounded in Macon County Sunday night, but officials said it was a false alarm.
The Macon County Emergency Management Agency said the outdoor warning siren located at the Long Creek firehouse was activated around 11 p.m. on Sunday. After looking into it though, officials said the activation happened after a control button was accidentally pressed.
Cancer survivors get together to celebrate National Cancer Survivors Day
Now, the Macon County EMA said they are working with the fire department to figure out a way to prevent a similar situation from happening in the future.
'We appreciate your understanding and want to reassure the public that steps are being taken to address this issue,' the Macon County EMA said in a statement posted to Facebook.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Iroquois County to retest warning sirens next week after sirens fail to sound
WATSEKA, Ill. (WCIA) — The Iroquois County EMA will be retesting all sirens across the county this upcoming Monday after the normal monthly test didn't go as planned. Coordinator for the county EMA Scott Anderson said in a press release Friday that following the regular monthly test of the warning sirens throughout the county, it was discovered that all the sirens — except for those in Watseka — failed to sound. As a result, all the sirens in the county will be re-tested between 10 a.m. and noon on June 9. NOAA weather radio stations coming back online after planned outage for NWS upgrades Additionally, Anderson said all residents need to remember that outdoor warning sirens are designed to be heard by those that are outside, not necessarily inside buildings or homes. He also recommends a number of other sources people can use to receive real-time warnings, including: NOAA Weather Radio: A national network that broadcasts continuous weather updates from the National Weather Service (NWS). Wireless Emergency Alerts (WEA): Sent to mobile phones by authorized government agencies such as NWS. Mobile Weather Apps: These apps provide severe weather alerts and more information. Local Media: Important sources of official storm watch and warning information. Emergency Alert System (EAS): This distributes alerts through a number of different media channels. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Medscape
2 days ago
- Medscape
Novo's Ozempic Linked to Rare Cases Of Serious Eye Disorder, EU Regulator Says
(Reuters) -Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to vision loss, the European Medicines Agency's safety committee said on Friday. In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic optic neuropathy (NAION). But this is the first time a regulator has confirmed the side effect. The condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Ozempic as well as in Novo's other diabetes drug Rybelsus, for at least one year, the regulator said. NAION is the second-most common cause of blindness due to optic nerve damage, after glaucoma. "This has been reported as a potential risk for some time, so I think the clinical community is relatively aware of it. I don't see this as making any major difference to prescribing patterns," said Barclays analyst Emily Field. U.S.-listed shares of the Danish drugmaker were up nearly 2.5% in early trading. The EMA, which started its review in December, has asked Novo to add NAION as a side effect of very rare frequency in the product information accompanying drugs that contain semaglutide. Novo said it would work with the EMA to update the labels, adding clinical trials and after-market studies did not suggest a reasonable possibility that the drugs caused the condition. The "benefit-risk profile of semaglutide remains favorable," the company said in a statement. Novo has recently faced investor concerns that it is losing its first-mover advantage in the highly competitive obesity treatment market, leading the company to oust CEO Lars Fruergaard Jorgensen in May. Wegovy and Eli Lilly's Zepbound currently dominate the weight-loss drug market, potentially worth about $150 billion by the next decade. The EMA said several large studies in type-2 diabetes patients have suggested that use of Novo's drugs could raise the risk of developing NAION by twofold. A study of nearly 350,000 diabetes patients published in March showed that the risk of developing NAION more than doubled after two years of treatment with Ozempic, compared to patients taking medicines from other classes. The U.S. Department of Health and Human Services did not immediately respond to a Reuters request for comment on whether the Food and Drug Administration was conducting a probe into the side effect. (Reporting by Manas Mishra and Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
Yahoo
2 days ago
- Yahoo
Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say
The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide following concerns regarding a possible increased risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition that may cause vision loss. Novo Nordisk A/S's (NYSE:NVO) semaglutide, a GLP-1 receptor agonist, is the active substance in certain medicines used for diabetes and obesity (Ozempic, Rybelsus, and Wegovy). After reviewing all available data on NAION with semaglutide, including data from non-clinical studies, clinical trials, post-marketing surveillance and the medical literature, the committee on Friday concluded that NAION is a very rare side effect of semaglutide (meaning it may affect up to 1 in 10,000 people taking semaglutide).Results from several large epidemiological studies suggest that exposure to semaglutide in adults with type 2 diabetes is associated with an approximately two-fold increase in the risk of developing NAION compared with people not taking the medicine. This corresponds to approximately one additional case of NAION per 10,000 person-years of treatment; one person-year corresponds to one person taking semaglutide for one year. Data from clinical trials also point to a slightly higher risk of developing the condition in people taking semaglutide compared with people taking a placebo (a dummy treatment). Therefore, EMA has recommended that the product information for semaglutide medicines be updated to include NAION as a side effect with a frequency of 'very rare.' In December, a study conducted in Denmark and Norway revealed a potential link between the use of semaglutide for type 2 diabetes and an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION). Additionally, New research suggests that GLP-1 receptor agonists, widely prescribed for diabetes and weight loss, may significantly raise the risk of age-related macular degeneration in older diabetic patients. A study published on Thursday in JAMA Ophthalmology by the University of Toronto researchers warns of a potential downside: increased risk of neovascular age-related macular degeneration (nAMD) in diabetic users. nAMD is a severe form of age-related macular degeneration characterized by the growth of abnormal blood vessels in the back of the eye. Analyzing medical data from over 1 million Ontario residents with diabetes, researchers identified 46,334 patients prescribed GLP-1 RAs, most of whom were taking semaglutide—likely Ozempic, since Wegovy was only recently approved in Canada. Patients on these medications were matched with participants not on GLP-1 RAs, sharing similar demographics and health profiles, and tracked for three years. The study found that diabetic patients taking GLP-1 RAs for at least six months had double the risk of developing neovascular AMD compared to non-users. Over a mean follow-up period of 2.4 years, 0.2% of the GLP-1 RA cohort progressed to nAMD compared with only 0.1% of control participants, resulting in an increased hazard for nAMD of 2.21 for the GLP-1 RA cohort. The risk was also highest in those with the longest duration of exposure. The Guardian report added that those on the medications for more than 30 months had over three times the risk. The risk was even greater in older patients and those with a prior stroke. Recent findings from the 2025 American Clinical Society of Oncology annual conference suggested that patients using weight loss drugs, including Ozempic, were about 33% more likely to be diagnosed with kidney cancer compared to matched individuals not using the medication. Price Action: NVO stock is up 2.45% at $74.43 at the last check Friday. Read Next:Photo by Tobias Arhelger via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? NOVO NORDISK (NVO): Free Stock Analysis Report This article Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
